Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

被引：1
|
作者：
Santos, Allan de Souza
Santos, Herbert Henrique de Melo
Salvino, Marco Aurelio
Silva, Sarah Queiroz
Lucas, Larissa Ferreira
Almeida, Alessandro de M.
Santos, Mariane Melo
Santos, Juliana Andrade
Hungria, Vania T. M.
Arruda, Maria da Gloria B.
Torres, Alex
Crusoe, Edvan De Queiroz
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141438
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients
    Crusoe, Edvan De Queiroz
    Salvino, Marco Aurelio
    Silva, Sarah Queiroz
    Santos, Herbert Henrique de Melo
    Santos, Allan de Souza
    Almeida, Alessandro de M.
    Vieira, Lucas de Oliveira
    Fonseca, Cleverson Alves
    Lucas, Larissa Ferreira
    Leal, Joanna
    Santos, Mariane Melo
    Santos, Juliana Andrade
    Adorno, Elisangela
    Hungria, Vania T. M.
    Arruda, Maria da Gloria B.
    BLOOD, 2020, 136
  • [2] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final results
    Crusoe, Edvan
    Santos, Juliana
    Leal, JOanna
    Santos, Herbert
    Santos, Allan
    Almeida, Alessandro
    Santos, Mariane
    Lucas, Larissa
    Queiroz, Sarah
    Fonseca, Cleverson
    Adorno, Elisangela
    Vieira, Lucas
    Hungria, Vania
    Salvino, Marco
    Arruda, Maria da Gloria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S130 - S130
  • [3] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS
    Crusoe, Edvan De Queiroz
    Leal, Joanna
    Santos, Juliana Andrade
    de Melo Santos, Herbert Henrique
    Santos, Allan de Souza
    Lucas, Larissa Ferreira
    Almeida, Alessandro de M.
    Chaves, Marcos
    Dutra, Daniela Dourado
    Hungria, Vania T. M.
    Salvino, Marco Aurelio
    Arruda, Maria da Gloria B.
    BLOOD, 2022, 140 : 7699 - 7700
  • [4] Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients
    Crusoe, Edvan de Queiroz
    Santos, Juliana
    Santos, Allan
    Santos, Mariane Melo
    Salvino, Marco Aurelio
    Adorno, Elisangela
    Moura, Alessandro
    Fonseca, Cleverson Alves
    Queiroz, Sarah
    Bomfim, Maria da Gloria
    Nicanor, Jamile
    Santos, Herbert Henrique
    Hungria, Vania
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E145 - E146
  • [5] Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients
    Crusoe, Edvan De Queiroz
    Leal, Joanna
    Salvino, Marco Aurelio
    Lucas, Larissa Ferreira
    Santos, Juliana Andrade
    Santos, Herbert Henrique de Melo
    Almeida, Alessandro de M.
    Santos, Allan de souza
    Chaves, Marcos
    Santos, Mariane Melo
    Silva, Sarah Queiroz
    Vieira, Lucas de Oliveira
    Fonseca, Cleverson Alves
    Adorno, Elisangela
    Hungria, Vania
    Arruda, Maria da Gloria B.
    BLOOD, 2021, 138
  • [6] Effects of Daratumumab(dara), Cyclophosphamide (C), Thalidomide (T) and Dexamethasone (D) Combination on Lymphocyte Populations of Transplant Eligible Newly Diagnose Multiple Myeloma Patients
    Santos, Allan
    Santos, Herbert
    Leal, Joanna
    Santos, Juliana
    Salvino, Marco
    Lucas, Larissa
    Santos, Mariane
    Hungria, Vania T. M.
    Torres, Alex
    Crusoe, Edvan de Queiroz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S178 - S179
  • [7] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
    Bhutani, Manisha
    Robinson, Myra
    Atrash, Shebli
    Watts, Nicole
    Paul, Barry
    Chhabra, Saurabh
    Korde, Neha
    Begic, Xhevahire
    Foureau, David M.
    Chung, David J.
    Pineda-Roman, Mauricio
    Koya, Brinda
    Varga, Cindy
    Ai, Jing
    Daniels, Natonya
    Norek, Sarah
    Sutton, Sara A.
    Anderson, Michelle B.
    Jewell, Ashley N.
    Eldridge, Paul W.
    Acampora, Donna
    Symanowski, James T.
    Costa, Luciano J.
    Usmani, Saad
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 4393 - 4395
  • [8] Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide, Thalidomide, Dexamethasone, and Daratumumab
    Santos, Allan
    Santos, Mariane
    Leal, Joanna
    Santos, Herbert
    Santos, Juliana
    Lucas, Larissa
    Salvino, Marco Aurelio
    Bomfim, Maria da Gloria
    Hungria, Vania
    Torres, Alex
    Crusoe, Edvan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S580 - S580
  • [9] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
    Sonneveld, Pieter
    Broijl, Annemiek
    Gay, Francesca
    Boccadoro, Mario
    Einsele, Hermann
    Blade, Joan
    Dimopoulos, Meletios A.
    Delforge, Michel
    Spencer, Andrew
    Hajek, Roman
    Schjesvold, Fredrik
    Lonergan, Sarah
    Smith, Elena
    Carson, Robin L.
    Crist, Wendy
    Garvin, Wendy S.
    Vermeulen, Jessica
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTD) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-Risk Patients in Cassiopeia
    Sonneveld, Pieter
    Attal, Michel
    Perrot, Aurore
    Hulin, Cyrille
    Caillot, Denis
    Facon, Thierry
    Leleu, Xavier
    Belhadj, Karim
    Karlin, Lionel
    Benboubker, Lotfi
    Levin, Mark-David
    Minnema, Monique C.
    Westerman, Matthijs
    Delforge, Michel
    Zweegman, Sonja
    Pei, Lixia
    de Boer, Carla
    Vanquickelberghe, Veronique
    Kampfenkel, Tobias
    Moreau, Philippe
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 124 - 126
12345